As he investigates Trump's aides, special counsel's record shows surprising flaws

Allergan sets up meeting to seek shareholder OK of Actavis acquisition

Allergan, Actavis schedule meetings March 10 to seek shareholder approval of their $66-billion deal

Allergan Inc., the Irvine company that makes Botox, scheduled a March 10 special meeting to seek shareholder approval of its acquisition by Irish firm Actavis.

Actavis agreed in November to pay about $66 billion in cash and stock to acquire Allergan, which had spent several months battling a hostile takeover attempt by Canadian company Valeant Pharmaceuticals International Inc.

The deal needs the approval of shareholders of both companies. Actavis has also scheduled a March 10 meeting to seek shareholder approval of the acquisition.

Actavis and Allergan expect to begin mailing a joint proxy statement — disclosing details of the sale — to their respective shareholders "in the coming days," the companies said in a news release.

In addition to popular wrinkle-erasing drug Botox, Allergan sells a line of ophthalmic medications and breast implants. Actavis, headquartered in Dublin, makes and markets pharmaceuticals used to treat a variety of diseases.

Before Actavis' offer, Valeant had teamed with hedge fund manager Bill Ackman in an attempt to acquire Allergan. But Allergan's board rejected Valeant's offers — its highest was about $53 billion — as too low.


Twitter: @spfeifer22

Copyright © 2017, Los Angeles Times
EDITION: California | U.S. & World